In particular, longitudinal imaging studies in which amyloid/tau deposition, structural brain changes, brain connectomics, and cognitive functioning are repeatedly assessed in patients with AD pathology and healthy controls may help to address these questions. This evidence concerns the gene MAPT and Alzheimer disease.